We are live on ! Find out more
APOPW

Cellect Biotechnology Ltd. Warrants to Purchase ADRs

Delisted

APOPW was delisted on the 3rd of August, 2021.

2 hedge funds and large institutions have $2K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 22 (0)

33% less capital invested

Capital invested by funds: $3K → $2K (-$1K)

Holders
2
Holders Change
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
1
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$24

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
CH
1
CVI Holdings
Delaware
$1K
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$1K +$24 +194 +1%

APOPW Hedge Fund Activity: Q2 2019 in Review

2 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q2 2019, worth a combined $2K — down 33% from $3K a quarter earlier.

Fund positioning in APOPW was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $24.

  • 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $2K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q2 2019, down 33% quarter-over-quarter.
  • 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q2 2019 and 0 closed out.
  • The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q2 2019 was Susquehanna International Group, an estimated $24 added.

Based on aggregated 13F filings for Q2 2019.